We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Solutions Designed for Labs to Reduce Costs and Improve Productivity Showcased at the AACC Expo

By LabMedica International staff writers
Posted on 02 Aug 2013
Print article
Abbott (Abbott Park, IL, USA) features solutions to help labs prepare for the evolving healthcare environment. US healthcare providers are playing an increasingly important role in clinical labs to prevent medical errors, lower readmission rates, and improve patient care. Abbott showcased solutions designed to meet the needs of its lab customers while reducing costs and improving productivity at the American Association for Clinical Chemistry (AACC) annual meeting and clinical lab expo, July 28–August 1, 2013 in Houston (TX, USA).

Abbott also featured a variety of its solutions, including the first US Food and Drug Administration (FDA; Silver Spring, MD, USA)- approved genotyping test for hepatitis C (HCV), the RealTime HCV Genotype II test; the FDA-cleared FreeStyle Precision Pro Blood Glucose and β-Ketone Monitoring System; as well as the Accelerator a3600, a laboratory automation track system.

In addition, Abbott also showcased the company’s approach to customer-focused innovation through its program called "Factoring in the Human." On its recently launched Web site (please see Related Links below). Abbott shares the company’s focus on human factor principles and customer-centric approaches to influence product design. Laboratory professionals are encouraged to visit the website to learn more.

"Clinical laboratories are looking for the right solutions to successfully address the complexities and opportunities presented by the changing healthcare environment," said Greg Ahlberg, divisional vice president, US Commercial Operations, Diagnostics, Abbott. "Abbott has one of the broadest and most flexible portfolios available today to help labs drive efficiency and optimization, leading to improved patient care."

More than 30 scientific posters and/or oral presentations related to Abbott’s solutions will be presented during the AACC program. Seventeen posters cover cardiac markers and 13 focus on the performance of several clinical chemistry assays as well as on important areas, such as transplant, endocrine, metabolic, and congenitals.

Related Links:

Abbott
Abbott - Factoring the Human
US Food and Drug Administration


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.